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curves were constructed. RESULTS: Eplerenone added incre-
mental beneﬁt on mortality and morbility above placebo. Costs
was $US1279.70 higher in the eplerenone treatment (CI 95%,
$US604-1992) because of the drug cost. For eplerenone versus
placebo, the incremental cost—effectiveness ratio (ICER) was
$US13,169.8 per LYG and $US19,753.4 per QALY gained.
Using a willingness-to-pay threshold of $US20,000 per LYG or
QALY gained, 64.3% of estimates fell below this threshold.
CONCLUSION: Eplerenone compared with placebo in the treat-
ment of heart failure after AMI is effective in reducing mortal-
ity and is cost—effective with a threshold of $US20.000 per LYG
in Mexico. These results should be taken into account by
Mexican decision makers and clinicians in the management of
patients with left ventricular systolic dysfunction and heart
failure following AMI.
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OBJECTIVES: To evaluate the cost-effectiveness of lipid-lower-
ing therapy for cardiovascular disease based upon the event risk
and LDL-C reduction relationship observed in the Clinical Treat-
ment Trialists (CTT) meta-analysis. METHODS: A simple
Markov model comparing the incremental cost-effectiveness for
two lipid-lowering therapies was developed using TreeAge® soft-
ware. The addition of ezetimibe to simvastatin 40 mg was com-
pared to doubling the simvastatin 40 mg dose from the UK health
plan perspective. Patients enter the model as a primary or sec-
ondary CHD prevention patient. Patients experience a fatal or
non-fatal CHD event, die from another cause, or remain event-
free in each annual cycle. Transition probabilities were deter-
mined by a patient’s baseline risk, age and LDL-C reduction.
Lipid therapy was assumed to provide a 23% reduction in major
coronary events for 1 mmol/L reduction in LDL-C. Costs and
utilities for health states were adapted from the NICE report on
statin therapies and were discounted at 3.5%. Base case analy-
ses were performed for a 55 year old individual, with or without
a history of CHD, annual CHD risk of 3%, and a baseline LDL-
C value of 4 mmol/L. Probabilistic sensitivity analysis (PSA) was
performed and acceptability curves were generated. RESULTS:
The incremental cost per QALY gained of simvastatin/ezetimibe
co-administration was estimated at ≤14,618 and ≤18,549 for
those with and without a history of CHD, respectively. PSA
based upon 10,000 iterations suggest that the ezetimibe co-
administration was below a threshold of ≤30,000/QALY gained
in over 95% of the simulations. Additional analyses suggest that
cost effectiveness of the addition of ezetimibe improves relative
to doubling of statin dose with increasing baseline CHD risk
and/or LDL-C levels. CONCLUSION: The model developed
provides a simple method to compare two treatments based on
their effects on LDL-C. Although the model has several simpli-
fying assumptions it provided results consistent with other CHD
models.
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OBJECTIVES: Cholesterol management guidelines recommend
management of elevated low-density cholesterol (LDL-C) fol-
lowed by management of low high-density cholesterol (HDL-C)
and elevated triglycerides in patients with dyslipidemia. The
objective of this study was to conduct a population-based 
cost-efﬁcacy analysis of dyslipidemic agents using data from 
the National Health and Nutrition Examination Survey III
(NHANES III). METHODS: A 6-month, cost-effectiveness
analysis, from a MCO perspective, incorporating dose escalation
and adverse drug effects (ADEs) associated with pravastatin,
simvastatin, ezetimibe/simvastatin, and extended release (ER)
niacin/lovastatin was conducted. Patients with high LDL-C and
low HDL-C from NHANES III were included to estimate pop-
ulation values for lipids, while product labeling was used 
for lipid changes. Goals for LDL-C were <100 mg/dL and 
<130 mg/dL based on cardiovascular risk; and, HDL-C > 40 or
50 mg/dL (males and females, respectively). Medication (WAC),
physician ofﬁce visits, and laboratory costs (Medicare’s
allowance fees) were included. Monte Carlo simulations were
conducted for probabilistic sensitivity analyses testing key
assumptions of drug efﬁcacy, ADEs, and costs. RESULTS: Rates
of lipid goal achievement was a function of sex, age and treat-
ment. Accounting for dosing and ADEs, the lowest cost for 180
days of treatment was ezetimibe/simvastatin ($561), followed by
ER niacin/lovastatin ($655), pravastatin ($698), and simvastatin
($742). Attainment of LDL-C and HDL-C goals was highest for
ER niacin/lovastatin (77.8%), followed by for ezetimibe/simvas-
tatin (50.1%), simvastatin (44.2%) and pravastatin (29.5%).
Cost/patient achieving combined goals was $842 for ER
niacin/lovastatin, $1120 for ezetimibe/simvastatin, $1677 for
simvastatin, and $2364 for pravastatin. Both pravastatin and
simvastatin were dominated by ezetimibe/simvastatin, while the
incremental cost-effectiveness for ER niacin/lovastatin at $341
per additional patient reaching goal was on the cost-effective
frontier. CONCLUSION: This analysis suggests among patients
with high LDL-C and low HDL-C treatment with ezetimibe/sim-
vastatin and ER niacin/lovastatin are cost-effective strategies
compared to either pravastatin or simvastatin.
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OBJECTIVES: To estimate the cost per patient successfully
treated to NCEP ATP-III goal with high-potency statins or
statin/combinations. METHODS: We constructed a decision
analytic model (from the payer perspective) comparing four
statins or statin combinations: atorvastatin (40–80 mg), rosu-
vastatin (10–40 mg), simvastatin/ezetimibe (Vytorin; 10/10–
10/40 mg), and simvastatin 80 mg. Costs were based on best
available Military Health System (MHS) prices, and only
included drug acquisition costs. Monte Carlo methods were used
to generate a distribution of starting LDL values for a hypo-
thetical cohort of 1000 patients. The mean starting LDL was
189.1 (SD = 18.6), with individual patient LDLs normally dis-
tributed. The percentage of patients in each NCEP ATP-III risk
group was: low risk 41% (LDL goal <160 mg/dl), moderate risk
30% (LDL goal <130 mg/dl), high risk 29% (LDL goal <100
mg/dl). Distributions of efﬁcacy values (% LDL reduction) based
on clinical literature were generated for each treatment arm. The
primary outcome was the percentage of patients successfully
treated to individual NCEP ATP-III goals based on starting LDL
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and risk group. The time horizon was one year, without dis-
counting. Sensitivity analysis was performed to account for
uncertainty. RESULTS: Vytorin was found to be most effective
with 90% of patients successfully treated to goal compared to
78.2%, 82.1%, and 82.2% for simvastatin, atorvastatin, and
rosuvastatin, respectively. Vytorin was the preferred strategy,
dominating other treatments at a cost of $431 annually per
patient successfully treated to goal. CONCLUSION: Using lit-
erature-derived estimates for % LDL lowering efﬁcacy, we com-
pared high-potency antilipidemics based on the percentage of
patients successfully treated to goal. Estimates were similar to
outcomes reported in clinical trials. At DoD drug acquisition
costs, Vytorin appeared to be the most cost effective.
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OBJECTIVES: In Mexico, hypertension and hypercholes-
terolemia are the main causes of cardiovascular risk and death
in adult population. Prevalence of hypertension and hypercho-
lesterolemia are estimated in 30% and 43%, respectively. The
purpose of this study was to evaluate the cost—effectiveness of
amlodipine/atorvastatin in a single pill therapy compared to
other local therapies for patients with both diseases from the
Mexican health care payer’s perspective. METHODS: We used
a ﬁve-year Markov analysis model to estimate costs and effec-
tiveness. Effectiveness measures were the % of patients with full
compliance and % of patients with fatal or non-fatal cardiovas-
cular events. Transition probabilities were obtained from inter-
national published literature. Comparators used in the model
were: amlodipine 5 mg, felodipine 5 mg, nifedipine 30 mg, cap-
topril 75 mg, enalapril 20 mg, losartan 50 mg all in combination
with pravastatin 10 mg (separate pills) vs. the comparator
amlodipine 5 mg + atorvastatin 10 mg (single-pill therapy). Esti-
mation of resource use was performed employing hospital
records from ﬁve hospitals of the Social Security Mexican Insti-
tute-IMSS in Mexico City (n = 75). They included hospitaliza-
tion, ICU, emergency, outpatient services and drugs. Costs and
effectiveness measures were discounted 3% annually. One-way
and probabilistic sensitivity analyses were performed and accept-
ability curves were constructed. RESULTS: The single-pill
therapy showed better compliance with 12.5% vs. 9.6% shown
in average by the other combinations considered (p < 0.01). This
higher compliance of the single-pill therapy yielded a signiﬁcant
reduction in the number of cardiovascular events, deaths and
expected costs (cost saving strategy). Alongside the time horizon
used, the model estimated that the single-pill therapy could save
US$2.8 per patient with both diseases. Sensitivity analyses
showed the same results. CONCLUSION: In Mexico, amlodip-
ine/atorvastatin within a single-pill showed better clinical and
economic outcomes in comparison to other combinations of
antihypertensive and statins inside an institutional setting. These
results should be considered by Mexican decision-makers in
future cost-containment policies.
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OBJECTIVES: To compare cost-effectiveness (CE) of rosuvas-
tatin (RSV) and ezetimibe/simvastatin (E/S) in patients with
treated dyslipidemia to assess achievement of treatment goals
established by Adult Treatment Panel III (ATPIII). METHODS:
Clinical data was obtained from the ﬁles of dyslipidemic patients
that attended from January 2004 to December 2005 to a Car-
diology Hospital in Mexico City. Patients treated with either
RSV 10 mg/day or E/S 10/20 mg/day and with lipid determina-
tions before (basal) and after 8 weeks of treatment were
included. The perspective of the analysis was from the point of
view of the provider, and the cost of the drugs that was obtained
by a local wholesaler (NADRO, Oct 2006). Effectiveness was
measured with subrogates end points, achieving ATPIII lipid
goals and lowering LDL-C levels. The precision of the CE esti-
mate was assessed by the bootstrap method, using 1000 re-sam-
plings and by net monetary beneﬁt approach. Horizon time was
8 weeks. Acceptability curves were built to assess uncertainty.
Sensitivity analysis included threshold, one-way and scenario
assessment. RESULTS: Ninety-eight patients received RSV (age
63.1 ± 12.4 years) and 89 patients received E/S (age 65.8 ± 12.8
years). In the RSV group 81.4% and 46.4% patients achieved
2001 and 2004 lipid goals respectively, versus 58.4% and 31.5%
E/S patients (p < 0.01). LDL-C mean percentage reduction was:
RSV −46.7 ± 13.6 versus E/S −35 ± 21.3 (p < 0.001). Average
per patient costs in USD was 94.35 for RSV (85.4–109.8) and
143.01 for E/S (127.42–161.64). RSV showed to be less costly
and more effective than E/S for achieving ATPIII goals and reduc-
ing LDL-C levels. Acceptability showed that independently of
willingness to pay, RSV is CE in 97% of scenarios compared to
E/S. Sensitivity analysis showed the robustness of results. CON-
CLUSION: On clinical practice RSV is more CE in attainment
of ATPIII goals and lowering LDL-C levels in Mexican patients.
PCV27
CLINICAL AND ECONOMIC BURDEN OF NONADHERANCE
TO LIPID-LOWERING AND ANTIHYPERTENSIVE THERAPY IN
A HYPERTENSIVE POPULATION
Cherry S1, Benner JS1, Hussein M1,Tang S2, Nichol MB3
1ValueMedics Research, LLC, Falls Church,VA, USA, 2Pﬁzer Global
Pharmaceuticals, New York, NY, USA, 3University of Southern
California, Los Angeles, CA, USA
OBJECTIVES: To determine the lifetime costs and morbidity
associated with nonadherence to lipid-lowering and antihyper-
tensive therapy in a population of hypertensive patients with
additional cardiovascular risk factors. METHODS: A Markov
model was constructed to assess the lifetime costs and outcomes
associated with different levels of adherence to lipid-lowering
and antihypertensive therapy in a cohort of patients aged 40 to
79 years. Three adherence scenarios were considered: no treat-
ment, typical adherence, and ideal adherence. Patient charac-
teristics were modeled on those of participants in the 
Anglo-Scandinavian Cardiac Outcomes Trial—Lipid-Lowering
Arm (ASCOT-LLA); event probabilities for coronary heart
disease and stroke were estimated using risk prediction algo-
rithms from the Framingham Heart Study. The ideal adherence
scenario modeled the experience of ASCOT-LLA patients, with
adherence levels based on those observed in the trial. The typical
adherence scenario employed real-world adherence rates and
annual transitions based on prescription records from the Cali-
fornia Medicaid system. Risk reductions for the various adher-
ence states in this scenario were drawn from clinical trials. Model
outputs included frequencies of primary and secondary heart
disease and stroke, life expectancy, and pharmacy-related and
event-speciﬁc costs in 2006 USD. RESULTS: The mean number
of events per patient was 0.738 in the no treatment scenario,
